End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.88 CNY | -.--% | -0.59% | -0.45% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The firm trades with high earnings multiples: 27.62 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.45% | 1.19B | - | ||
-9.59% | 7.67B | B- | ||
-1.20% | 5.41B | B | ||
+26.10% | 4.62B | C | ||
+0.02% | 4.57B | C | ||
-53.02% | 3.22B | D+ | ||
+6.42% | 2.59B | - | - | |
-14.95% | 2.05B | B- | ||
-8.29% | 1.79B | D+ | ||
+0.42% | 1.76B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300685 Stock
- Ratings Amoy Diagnostics Co., Ltd.